TELO:NASDAQ, Telomir Pharmaceuticals, Inc.

Why TELO stock fell on November 12

Telomir Pharmaceuticals, Inc. fell 16.0% on Thursday, November 12, 2026, on 230,400 shares, 2.0 times its average daily volume. No headline about TELO came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

TELO stock overview

Telomir Pharmaceuticals, Inc. (TELO:NASDAQ) closed at $0.423 on November 17, 2026, down 12.04% on the day. The stock trades 73.2% below its 52-week high of $1.58 and 5.5% above its 52-week low of $0.401. Over the past year, it lost 70.4%. Telomir Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price
$0.423
Day change
-12.04%
Volume
326,017
Average volume
114,195
Market cap
31M+
52-week range
$0.401 – $1.58
50-day average
$1.03
200-day average
$1.19

Price action over the past year

In 252 trading sessions since November 17, 2025, TELO closed higher on 105 days (42%). Its best day was July 21, 2026 (+17.52%) and its worst was July 20, 2026 (-17.21%). The stock moved 10% or more in a single session 9 times.

Recent signals

TELO news

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis.

Similar stocks

Find more stocks like TELO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.